Chelsey B. Weatherill

Chelsey B. Weatherill

Auto-generated profile, based on publicly available information

Chelsey B. Weatherill

Hoag Family Cancer Institute Newport Beach California USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Clinical Genetics
Verified
Journal Article
Closed access
CWChelsey B. Weatherill
Chelsey B. Weatherill
SBSarah A. Burke
Sarah A. Burke
CHCarolyn G. Haskins
Carolyn G. Haskins
DLDarcy K. Berry, MS, LCGC
Darcy K. Berry, MS, LCGC
JHJeanne P. Homer
Jeanne P. Homer
Sourat DarabiSourat Darabi
Sourat Darabi

1 November 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
JHJeanne P. Homer
Jeanne P. Homer
MDMichael J. Demeure
Michael J. Demeure
YYYuhui Yao
Yuhui Yao
KHKristen Hanson
Kristen Hanson
BRBrenda Ramczyk
Brenda Ramczyk
CRCharité N. Ricker
Charité N. Ricker
Purpose: To estimate the relative and absolute risks (ARs) for ovarian, prostate, male and female breast, pancreatic, biliary tract, and colorectal cancers associated with germline BARD1 pathogenic and likely pathogenic variants (PVs/LPVs) because these risks have not previously been reported from a genotype-first perspective. Methods: We performed a secondary retrospective analysis of multicenter data comprising 445 three-generation pedigrees with confirmed BARD1 PVs/LPVs from 25 institutions nationwide. Data were aggregated at the family-relatedness level. The risks were estimated using a Bayesian survival model that incorporated information from the Surveillance, Epidemiology, and End Results (SEER) Program. Results: We confirmed the previously established increased risk for female breast cancer (relative risk [RR] = 3.53; 95% CI, 1.95 to 5.81; posterior probability [PP] = 0.0040) and found positive associations with female pancreatic cancer (RR = 3.76 [95% CI, 2.16-7.25]; PP < .0001), male pancreatic cancer (RR = 2.89 [95% CI, 1.66 to 5.61]; PP < .0001), and prostate cancer (RR = 3.02 [95% CI, 1.95 to 4.71]; PP < .0001). The predictive ARs to age 85 were 41.84% (95% CI, 23.09 to 68.91) for female breast cancer, 4.80% (95% CI, 2.76 to 9.25) for female pancreatic cancer, 3.98% (95% CI, 2.29 to 7.73) for male pancreatic cancer, and 36.11% (95% CI, 23.29 to 56.29) for prostate cancer. Risk estimates suggest an association for male breast, ovarian, and female colorectal cancers; however, the clinical significance is unclear, and these findings warrant cautious interpretation. In contrast, we found no evidence of association for biliary tract cancer or male colorectal cancer. Conclusion: These results support BARD1 's association with female breast cancer and suggest associations with pancreatic and prostate cancers. These findings have potential implications for genetic counseling and personalized risk management for male and female BARD1 PV/LPV heterozygotes.